Preliminary Third Party Report Leads St-George to Accelerate Plans to File for Patents on Extraction for Lithium in Clays
Momentum Public Relations
Press Release: December 27, 2017
St-Georges Eco-Mining Corp. (CSE: SX) (OTC: SXOOF) (FSE: 85G1) is pleased to release the findings of the preliminary report provided by the third party contractor hired to execute certain tests in relation to St-Georges’ research initiatives related to the extraction of lithium in clays.
The first stage of the mandate given to Dundee Sustainable Technologies (CSE:DST) was to characterize the material from the Bonnie Claire Lithium Property – provided by Iconic Minerals Ltd (TSX-V: ICM) – and to test it using currently knowns extraction techniques, commercially deployed or known in the public domain from academic research. St-Georges will work strategically with all the potential suppliers to optimize for total cost of ownership and develop a green foot print. This will include solvent extraction, membranes and electrolysis to make a lithium product that meets or exceeds industry standards.
The extraction techniques evaluated can achieve recoveries between 80% to 99.9% with a purity of 99.9%. St-Georges is focused on total capital and operating costs with a green foot print. The ecological focus is achieved, in part, by converting by products into saleable forms. St-Georges management is encouraged by the recent developments and is now looking to expand the scope of its analysis in regards to what might be patentable in its extraction methods.
The economic nature of St-Georges proposed technology in relation to the Bonnie Claire project cannot be established prior to the definition of a NI 43-101 Resources Estimate and a Preliminary Economical Assessment of the Bonnie Claire Project. However, the characterization of the material provided by Iconic to St-Georges allows for a certain amount of limited hypothesis. The high percentage of silica and alumina characterized in the material processed from Bonnie Claire makes an already interesting concentration of lithium stand out in the remaining segregated material. The report also hint at are other elements that might be worth recovering like potassium and other agricultural focused by products. The next phase of process optimization will be initiated in January. St George is encouraged by the initial characterization results.
Enrico Di Cesare, St-Georges’ director and vice-president research & development commented: “We are looking forward to working closely with the Iconic exploration team and characterizing and testing the results in parallel of their exploration effort on Bonnie Claire. Our technical team is looking forward to optimizing the process for recovery of lithium and salable by-products with a focus on being ecologically green”.
“(…) Our R&D initiative related to lithium bearing clay is progressing well. Shareholders and stakeholders need to keep in mind however that we still have more challenges in the near future. The next 2-3 months will be critical for the development of the lithium-in-clay (LiC) extraction process. It’s important to note when studying the history of science that a significant amount of disruptive technologies never made it outside of a controlled laboratory environment. The demonstration of commercial scalability is still the make or break milestone that we need to secure and we do not have any guarantee of success at this point in time. If that milestone is achieved, we will then have the privilege of embarking into the exciting endeavor of bringing a mine to production. (…) over the months and years period that this task might entails” – said St-Georges’ CEO Frank Dumas.
ON BEHALF OF THE BOARD OF DIRECTORS
“Enrico Di Cesare
ENRICO DI CESARE, DIRECTOR, VICE-PRESIDENT RESEARCH & DEVELOPMENT
About St-Georges
St-Georges is developing new technologies to solve the some of the most common environmental problems in the mining industry.
The Company controls directly or indirectly, through rights of first refusal, all of the active mineral tenures in Iceland. It also explores for nickel on the Julie Nickel Project & for industrial minerals on Quebec’s North Shore and for lithium and rare metals in Northern Quebec and in the Abitibi region. Headquartered in Montreal, St-Georges’ stock is listed on the CSE under the symbol SX, on the US OTC under the Symbol SXOOF and on the Frankfurt Stock Exchange under the symbol 85G1. For additional information, please visit our website at www.stgeorgesplatinum.com
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
- Published in St-Georges Eco-Mining
ATW Tech Completes a Private Placement of Units of $423,640
Momentum Public Relations
Press Release: December 22, 2017
AtmanCo inc. (“AtmanCo” or the “Company”) (TSX-V:ATW) is pleased to announce the closing of a private placement consisting of the issuance of 3 530 333 units at a price of $0.12 per unit, for total gross proceeds of $423,640. Each unit consists of one common share and one common share purchase warrant giving the holder the right to subscribe for one common share at a price of $0.15 from a period of 3 years.
The securities issued under this private placement are subject to a four-month hold period. This private placement remains subject to the approval of the TSX Venture Exchange. A commission of $840 is paid to a broker.
Additional information regarding the Company is available on SEDAR www.sedar.com. The TSX Venture Exchange and its Regulatory Services provider (as per meaning assigned to this term in TSX Venture Exchange’s policies) bear no liability as to the relevance or accuracy of this press release.
ABOUT ATW TECH
ATW Tech (‘AtmanCo’) (TSX-V:ATW) is a leader in information technology, owner of several web platforms including VoxTel, Québec Rencontres, VuduMobile, Atman and Bloomed. VoxTel offers various interactive landline and mobile carrier billing phone solutions. Quebec Rencontres is a web and mobile social network application catered to building serious and sustainable relationships. VuduMobile is specialized the text messaging business for enterprises through its unique, user-friendly and bilingual test messaging application et turnkey solution allowing management of text message management programs in all kind of businesses. Atman and its APIs enable companies to optimize their human capital. Bloomed is a cloud-based platform to manage data (smart data) on consumers and their behaviors, which is developed for marketing agencies and their campaigns for the consumer and corporate markets.
SOURCE:
ATW TECH (AtmanCo) | ||
Michel Guay | Simon Bédard, CA, CPA, CFA, MBA | |
Founder, president and CEO | CFO | |
Tel.: 514.935.5959 ext. 301 | Tel. : 514.935.5959 ext. 304 | |
mguay@atmanco.com | sbedard@atmanco.com | |
www.atwtech.com |
- Published in Atmanco
Tetra Bio-Pharma Announces the Signature of a Letter of Intent to Monetize GrowPros and its Late Stage ACMPR Application
Momentum Public Relations
Press Release: December 21, 2017
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with a private Canadian corporation (the “Purchaser”) and has started a transaction to monetize GrowPros (GrowPros MMP Inc., Tetra’s wholly-owned subsidiary) (the “Potential Transaction”), to allow Tetra to focus its activities on the drug development and its clinical trials of its pharmaceutical business. With this transaction, Tetra is expected to receive $350,000 and ensure another supply source of cannabis with pharmaceutical GMP quality for the pipeline of products under development.
It is expected that the Proposed Transaction would include the following main terms:
- Acquisition by the Purchaser of all the issued and outstanding shares of GrowPros held by the Company;
- Tetra will receive $350,0000 for the Potential Acquisition composed of (i) a first installment of $175,000 which was paid at the time of the signing of the LOI, (ii) a second installment of $175,000 which will be paid following signing of the definitive agreement giving effect to the LOI (the “Definitive Agreement”) and (iii) subject to stock exchange and securities regulatory approval and following the Purchaser’ initial public offering, 15,000,000 common shares of the Purchaser which would represent approximately a 33% equity interest in the share capital of the Purchaser post-initial public offering. The intention is for Tetra to eventually distribute these shares as a dividend in kind to its shareholders on a pro-rated basis;
- Purchaser’s responsibility to move GrowPros’ late stage ACMPR application forward (submitted in November 2014) with Health Canada;
- Grant by Purchaser and GrowPros of a right of first refusal to the Company on future cannabis production by GrowPros, which will ensure a second source of cannabis to the Company with pharmaceutical GMP quality for the production of the pipeline of products under development;
- Undertaking by the Purchaser to build a 15,000 square feet production facility located on 145 acres of agricultural land in Venosta, Quebec. The property has been approved for up to 1.5M square feet of production space; the Purchaser will ensure that a dedicated part of that production facility will be in compliance with good manufacturing practices for pharmaceutical product; construction of the production facility is expected to begin in the first quarter of 2018.
“We are very happy to leverage this asset that is Grow Pros. By finding a reliable partner, Tetra expects not only to immediately increase its cash flow, but also to enable its shareholders to maintain an investment in the high growth cannabis industry. As importantly, Tetra is further focusing on its core expertise and strength: the development of prescription drugs through the highest levels of clinical trials. Finally, we expect this deal to allow us to secure our production of dried cannabis for our lead drug candidate for its expected approval and eventual commercialization, and provide us with another partner from which we can supply our active pharmaceutical ingredients (API) for our drug development programs.” says Bernard Fortier, CEO of Tetra.
The Proposed Transaction contemplated by the LOI is subject to a number of significant condition precedents including but not limited to the entering into of the Definitive Agreement on terms satisfactory to both parties, the completion of the Purchaser’s initial public offering and receipt of all requisite approval (including stock exchange and regulatory approvals).
The parties intend to enter into the Definitive Agreement and close the Proposed Transaction by the end of the first quarter of 2018.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
- Published in Medical Marijuana, Tetra Bio Pharma
Albert Mining to Use its CARDS “Artificial Intelligence Technology” to Target Copper, Zinc, and Silver on Falco Resources Inc.’s Mining Properties in Rouyn-Noranda
Momentum Public Relations
Press Release: December 19, 2017
Albert Mining Inc. (the “Company” or ” Albert “) (TSX-V: AIIM ), an exploration mining company and a leader in the use of artificial intelligence and advanced knowledge-extraction techniques in the mining sector, is pleased to announce that its techn ology will be used on Falco Resources Inc. (” Falco “) (Venture TSX: FPC ) 67,258 hectares properties in the Rouyn-Noranda region of Quebec. A fee of $90,000 will be paid to Albert for its CARDS (Computer Aided Resources Detection Software) services.
“Mrs. Claude Pilote, Senior project engineer of Falco, stated: “During the last few years, we made important progress at the Horne 5 deposit outlining a Measured Mineral Resources of 769,885 oz. AuEq (9,259,600 tonnes at 2.59 g/t AuEq, gold equivalent) and Indicated Mineral Resources of 6,731,443 oz. AuEq (81,855,200 tonnes at 2.56 g/t AuEq). With its positive feasibility study on the Horne 5 project, one of Falco’s objectives is to increase these resources on its 67,258 hectares properties. We believe that the CARDS technology will make it possible for us to develop new exploration targets on our properties and focus our efforts in high potential zones.”
By using its CARDS technology, Albert will assist Falco in identifying targets and possible sites with the same signature as known mineralized occurrences. Albert uses its proprietary technology to analyze geological, geophysical, and geochemical to discover the patterns hidden in the large amount of data that Falco owns.
About Albert Mining Inc. – Where Artificial Intelligence Meets Geology
Albert is a junior mining exploration and services company with an extensive portfolio of gold, copper, and diamond properties in Quebec. Albert also recently acquired all assets from DIAGNOS Inc.’s mining division, including the Computer Aided Resources Detection System (“CARDS”). Albert can count on a multidisciplinary team that includes professionals in geophysics, geology, Artificial Intelligence, and mathematics.
For further information, please contact:
Michel Fontaine
President and CEO of Albert Mining Inc.
Telephone: 514-994-5843
Email: michel@albertmining.com
Website: www.albertmining.com
Additional information about the Corporation is available under Albert’s profile on SEDAR atwww.sedar.com .
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or are events or conditions that “will”, “would”, “may”, “could” or “should” occur or be achieved. This news release contains forward-looking statements, pertaining to, among other things, the following: the resumption of the trading of Albert shares on the TSX Venture Exchange. Statements regarding future production, capital expenditures and development plans are subject to all of the risks and uncertainties normally incident to the exploration for and development and production of oil and gas that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. These risks include, but are not limited to, inflation or lack of availability of goods and services, environmental risks, drilling risks, regulatory changes and certain other known and unknown risks detailed from time to time in Albert’s public disclosure documents, copies of which are available on Albert’s SEDAR profile at www.sedar.com .
Although Albert believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. Albert’s actual results may differ materially from those expressed or implied in forward-looking statements and readers should not place undue importance or reliance on the forward-looking statements. Statements including forward-looking statements are made as of the date they are given and except as required by applicable securities laws, Albert disclaims any intention or obligation to publically update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Albert Mining, Artificial Intelligence, Mining
AREV Nutrition Sciences Inc. Announces Shares For Debt
Momentum Public Relations
Press Release: December 14, 2017
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CNSX – ARV ), announces that pursuant to an outstanding debt owed to a previous Director of the Company, it has issued an aggregate of 45,000 common shares at a deemed price of $0.50 share as consideration for the outstanding debt in the Company.
For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com.
On behalf of the Board,
Stephane Maher
Chief Executive Officer & Director
About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. (“AREV”), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain management, Insomnia, Central Nervous System Disorders & Sexuality.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
- Published in AREV Nutrition Sciences
Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC
Momentum Public Relations
Press Release: December 13, 2017
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D) agreement with Constance Therapeutics for the pharmaceutical drug development, and eventual commercialization in Canada, of their standardized, patent-pending, medicinal cannabis extract products. In addition to this agreement, the Company further strengthens its R&D program by means of a National Sciences and Engineering Research Council of Canada (NSERC) grant in its collaborative project with Dr Stan Kubow at McGill university.
Constance Therapeutics has developed whole plant cannabis extracts that have shown significant clinical promise in the treatment of various forms of cancer and improved patient survival as well. In collaboration, Tetra and Constance Therapeutics now aim to define the therapeutic mechanism and demonstrate efficacy of these cannabis extracts in the treatment of human cancers. In accordance with Tetra’s provisional patent announced on May 17th, 2017, the collaboration will focus on treating various forms of cancer driven by inappropriate Hedgehog signaling, including multiple forms of brain, blood, skin and bone cancers.
Constance Finley, Founder and CEO of Constance Therapeutics, Inc. said, “over the years, research has demonstrated that cannabinoids including specific terpenes, reduce and inhibit tumor growth in various animal models. Early clinical studies suggest cannabinoids enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers, such as Glioma, compared to controls.”
“We are very excited to achieve this co-development program with Constance Therapeutics” added Bernard Fortier, CEO of Tetra. “Their initial research is very promising and we are hopeful that together we can provide novel treatments for multiple forms of aggressive cancer to patients with limited therapeutic options. ”
In addition, Tetra is pleased to announce that the company has been awarded an additional Engage Plus grant from the National Sciences and Engineering Research Council of Canada (NSERC) to continue the collaborative project with Dr. Stan Kubow of McGill University. The goal of the basic research project is to explore and develop patentable cannabis-derived retail supplements and drug products in partnership with McGill University, and the grant awarded by NSERC will bolster Tetra Bio-Pharma’s investment with matching funds up to a maximum of $12,500.
“We are excited and honored to have the continued support of NSERC on this innovative project with McGill. Through the use of Dr. Kubow’s expertise and access to the advanced facility at McGill University, we aim to develop novel natural health supplements and drug products to be commercialized by Tetra,” commented Dr. Guy Chamberland, Chief Scientific Officer or Tetra Bio-Pharma.
Together, the co-development project focused on treating Hh-driven disease and the continuation of the McGill collaboration aiming to develop new cannabis-based products diversifies and strengthens Tetra’s pre-clinical program, thus ensuring the continuity of the product pipe-line in the future.
Lassen U, Mau-Sørensen M, Poulsen HS Orphan drugs in glioblastoma multiforme: a review Orphan Drugs: Research and Reviews 2014:4; 83-91
About Constance Therapeutics:
Constance Therapeutics, Inc. is a manufacturer and licensor of cannabis products designed to enable medical professionals to offer their patients a broader array of treatment options. The products fill the gap between traditional pharmaceuticals and commonplace cannabis products through manufacturing protocols using highly controlled, quantitatively-defined and patented processes. The products are third-party tested in the industry’s most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in San Francisco, California, Constance Therapeutics’ products have historically been accessed exclusively for therapeutic use and could only be purchased by registered California patients, in keeping with Proposition 215, and California Senate Bill 420.
More information at: www.constancetherapeutics.com
About Dr. Stan Kubow:
Dr. S. Kubow, Ph.D. is an Associate Professor at the School of Dietetics and Human Nutrition, McGill University. His research interests include the impact of nutritional interventions on a variety of disease outcomes and metabolic disorders using technologically modified food extracts and isolates with enhanced bioactivity including phytochemical extracts, whey and soy proteins and probiotics. These studies have been focused upon oxidative stress, inflammatory indices, lipoprotein, fatty acid and glucose metabolism as related to cell signaling pathways and disease pathogenesis.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
- Published in Uncategorized
AREV Nutrition Sciences Inc. Orders Second Extraction System for Jamaica
Momentum Public Relations
Press Release: December 13, 2017
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CNSX – AREV ), is pleased to announce that a second extraction system (“extractor”) has been ordered from Alternative Extracts Inc. (AEI) for delivery to Jamaica.
The extractor arrived in Quebec today for modifications that will increase its production capacity from 20 litres to 80 litres. Once the modifications are completed, the extractor will be shipped to a preferred partner in Jamaica that is still to be determined. AREV is in discussions with two potential companies and will select the company that aligns with the company’s vision.
The AEI extractor, removes oils without the use of destructive high-temperature, steam distillation or aggressive solvents and is the only known extractor to combine alcohol and CO 2 supercritical and critical technologies in one efficient process. AREV’s first system from AEI is the only known system to use ethanol, supercritical and subcritical CO2 technologies combined in a single system. It also allows more than one extract to be drawn from a single biomass, and for collection of extract fractions. The second system has been designed specifically to meet the needs of AREV’s partners in Jamaica.
“We are very excited to be ordering our second extractor and look forward to expanding our network with a strategic partner in Jamaica,” says Stephane Maher, CEO of AREV Nutrition Sciences Inc.
More details will be announced as final commitments are made. For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com or www.alternativeextracts.com for information on the company’s extraction systems.
On behalf of the Board,
Stephane Maher
Chief Executive Officer & Director
AREV Nutrition Sciences Inc.
Backgrounder of the AEI IP
FFE enables the extraction of fractions that are mostly lost when using common methods. In addition, yields match or exceed industry standards. The process uses food grade solvents that chill the biomass by adiabatic cooling while extracting at low pressures. The solution is passed into a collection chamber, which is held under vacuum. In this chamber the extraction agent evaporates and is recycled online after filtration and cleaning.
FFE technology is elegant, compact, fully scalable and economical compared to other methods. A fully functional plant with the capacity of processing 1,400 tons/annum of biomass can fit on 150 square metres of total floor space, compared with 1,000 square meters needed for similar capacity solvent or CO 2 plant. These systems are fully scalable and can be expanded to process thousands of acres of hemp, hops or cannabis each harvest.
The key competitive advantages of the FFE process are that it:
- 1. Operates at lower temperatures avoiding the destruction of vital components.
- 2. Produces extract of superior quality and yields to those that are heated or x-rayed or micro waved.
- 3. Uses equipment manufacture and less expensive to operate.
- 4. Significantly speeds up the extraction process.
- 5. Does not generate undesirable effluents.
- 6. Can be used on many different biomass types including Cannabis, industrial hemp and hops and coconut meat.
About AREV
ARE V Nutrition Sciences Inc. (“AREV”), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain management, Insomnia, Central Nervous System Disorders & Sexuality.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
- Published in AREV Nutrition Sciences, Marijuana
PROPERTY ACQUISITION PROGRESS RESTATEMENT
Momentum Public Relations
Press Release: December 11, 2017
On Dec. 8, 2017, Crystal Lake Mining Corp. issued a property update and it wishes to add to and clarify several items contained therein.
The subject Emo, Ont., properties are specifically located in Dobie, Kingsford, Mather, Potts and Tait townships, in the Dogpaw Lake and Heronry Lake areas.
The company has commissioned Ronacher McKenzie Geoscience to prepare an independent technical report in accordance with National Instrument 43-101 — Standards of Disclosure for Mineral Projects — on the properties.
All claim blocks are within 60 kilometres of each other. The target is Ni-Cu-PGE (nickel-copper-platinum-group-elements) mineralization, however, the exact geological characteristics of the claim blocks remain to be determined.
The geological content of this press release was reviewed by Dr. Elisabeth Ronacher, PhD, PGeo, a qualified person in accordance with in accordance with National Instrument 43-101 — Standards of Disclosure for Mineral Projects.
About Crystal Lake Mining Corp.
Crystal Lake Mining is a mineral exploration/development company focused on creating value through the exploration and development of its British Columbia and Ontario mineral properties.
We seek Safe Harbor.
- Published in Crystal Lake Mining, Mining
Tetra Bio-Pharma provides update on status of its Phase 3 Clinical Trial Application of Lead Drug Candidate PPP001
Momentum Public Relations
Press Release: December 11, 2017
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process. As such, the quality certification for the manufacturing of PPP001 will take place prior to the approval of its clinical trial protocol as Health Canada assesses its partner Aphria’s operations for Good Manufacturing Practices (GMP) for pharmaceutical products. Tetra agrees to this change from Health Canada because it is in the best interest of patients.
This change in the usual CTA approval process is expected to potentially extend the review process by 30 days. Tetra continues to expect PPP001 to become the first cannabis-derived inhalation drug to receive a drug identification number (DIN) from Health Canada, as well as pharmaceutical drug status from the FDA. The phase 3 trial should therefore begin in early 2018. The Company expects this change to have only a minor impact on time to market for PPP001.
Tetra received approval for the ethics review board on November 6th and subsequently submitted a Clinical Trial Application (CTA) for its Phase 3 clinical trial in cancer patients. This trial is expected to be a landmark clinical trial and is the first of its kind, enrolling a total of 946 subjects. Dr Guy Chamberland, Tetra’s Chief Scientific Officer (CSO) commented that: “a GMP certification from Health Canada’s drug inspectorate is welcome as this certification will signal to the company that its manufacturing partners comply with GMP requirements for drug approval and increases the measures put in place to ensure patients’ safety.” Once the trial is initiated, The Company will accelerate enrolment by expanding the number of clinical sites as it aims to adhere to its target date for filing PPP001 as a prescription drug (with a drug identification number – DIN) to Health Canada.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Rx Princeps™product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
www.tetrabiopharma.com
- Published in Medical Marijuana, Tetra Bio Pharma
Crystal Lake adds three properties to acquisition
Momentum Public Relations
Press Release: December 8 2017
Crystal Lake Mining Corp. has made progress on its acquisition of the minerals rights to the Emo, Ont., properties referred to in previous news as Property 1, Property 5, Property 7 and Property 8. The company agreed to purchase a 100-per-cent interest in those properties by paying $50,000 and issuing 10.5 million shares to Emerald Lake Development Corp., subject to a 2-per-cent net smelter royalty, 1 per cent of which may be purchased for $1-million.
The company received conditional approval to the acquisition on Nov. 14, 2017, which required, among other things, the preparation of a current geological report and demonstrated ability to finance the first stage of work on the properties. The company has commissioned Ronacher McKenzie Geoscience to prepare the requisite National Instrument 43-101 report on the properties, and, due to its recent fundraising initiatives, the company now has the financial resources necessary to finance the initial stage of consequently recommended exploration.
The company is pleased that acquisition has since been expanded to include additional properties known as Property 2, Property 3 and Property 4, and the added properties will be included without additional consideration. All of the claim blocks are in the same area and have similar geological characteristics to the EL1 and EL5 property blocks, which the company currently holds under option, targeting nickel, copper, cobalt and platinum group metal massive sulphides.
The company is expecting final approval shortly after the receipt of the pending geological report.
About Crystal Lake Mining Corp.
Crystal Lake Mining is a mineral exploration/development company focused on creating value through the exploration and development of its B.C. and Ontario mineral properties.
We seek Safe Harbor.
- Published in Crystal Lake Mining, Mining